Remnants of triglyceride-rich lipoproteins of both intestinal and liver origin are considered atherogenic, but they have been difficult to isolate and measure. An assay has been developed that allows the measurement of remnant-like particle cholesterol (RLP-C) and triglyceride (RLP-TG). RLP-C and RLP-TG concentrations were measured in >3000 fasting plasma samples obtained from participants in exam cycle 4 of the Framingham Offspring Study and stored at ؊80°C. Increased serum triglyceride is frequently associated with coronary heart disease (CHD) 5 in univariate analyses, but associations generally do not remain significant after adjustment for other CHD risk factors (1-3) . Chylomicrons produced in the intestine rapidly undergo lipolysis via the action of the enzyme lipoprotein lipase when they reach the bloodstream. During this process these triglyceride-rich lipoproteins (TRLs) lose much of their triglyceride and C apolipoproteins (apos), and gain cholesteryl ester and apo E via the action of cholesteryl ester transfer protein. These particles are then known as chylomicron remnants and contain apo B-48 and apo E as their major protein components. The final step in chylomicron remnant metabolism is uptake by the liver.
Increased serum triglyceride is frequently associated with coronary heart disease (CHD) 5 in univariate analyses, but associations generally do not remain significant after adjustment for other CHD risk factors (1) (2) (3) . Chylomicrons produced in the intestine rapidly undergo lipolysis via the action of the enzyme lipoprotein lipase when they reach the bloodstream. During this process these triglyceride-rich lipoproteins (TRLs) lose much of their triglyceride and C apolipoproteins (apos), and gain cholesteryl ester and apo E via the action of cholesteryl ester transfer protein. These particles are then known as chylomicron remnants and contain apo B-48 and apo E as their major protein components. The final step in chylomicron remnant metabolism is uptake by the liver.
The liver also produces TRLs, known as VLDLs. Like chylomicrons, VLDLs have a density of Ͻ1.006 kg/L. Newly formed VLDLs also undergo lipolysis, losing much of their triglyceride and apo C and gaining a cholesteryl ester and apo E. They are then known as VLDL remnants and contain apo B-100 and apo E as their major protein components. VLDL remnants can undergo additional metabolism to form intermediate density lipoproteins (density 1.006 -1.019 kg/L) and LDLs (density 1.019 -1.063 kg/L). Alternatively, they can be taken up directly by the liver. Like intermediate density lipoproteins and LDLs, both chylomicron remnants and VLDL remnants are thought to be atherogenic (4 -10) .
Although assays for direct measurement for LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) are routinely available (11) (12) (13) (14) (15) , assays for measurement of remnant lipoproteins have not been available until recently (16 -18) . Remnant isolation offers the potential benefit of allowing for the measurement of atherogenic particles within TRLs without measuring newly formed TRLs that are possibly nonatherogenic. In the past, remnant lipoproteins past have been difficult to isolate because they are extremely heterogeneous in size, co-migrate in the same density region as other TRLs, and contain the same lipid and apolipoprotein composition. Studies have shown, however, that these particles can remain in the circulation for an extended period of time, postprandially, even in individuals with low fasting triglyceride concentrations (19 -23) . Moreover, these remnant particles can increase dramatically in the nonfasting state, and there may be a wide degree of variability in this postprandial response among individuals. Methodology developed by Nakajima and co-workers (16 -18) uses antibodies to isolate a subset of TRLs that are enriched in apo E and display remnant-like characteristics. In this study, we evaluated measurements of these remnant-like particles (RLPs) in a large American population for the purpose of generating reference ranges and examining the effects of gender, age, and menopause as a basis for additional case-control and prospective evaluations of RLP-cholesterol (RLP-C) and -triglyceride (RLP-TG) concentrations as markers of CHD risk.
Materials and Methods study subjects
Subjects for the study included 3175 participants in exam cycle 4 (1987 through 1990) of the offspring population of the Framingham Heart Study (FHS), as part of an ongoing approved protocol. Subjects ranged in age from 22 to 81 years (mean age, 52 years). Information concerning alcohol intake (number of ounces per week), smoking (yes/ no), height, weight, systolic blood pressure, and diastolic blood pressure were collected at the time of examination (24) . Persons reporting any regular cigarette use within the year before the exam were classified as smokers. Body mass index was calculated as weight in kilograms divided by the square of height in meters. Women reporting no menses within the year before the examination were considered to be postmenopausal. Individuals excluded from the analyses included 65 individuals with triglyceride concentrations Ͼ4.5 mmol/L (400 mg/dL), 3 individuals with missing triglyceride data, 126 additional individuals on lipid-lowering therapy, and 160 additional women receiving hormonal replacement therapy, for a total of 354 excluded individuals. The final study set consisted of 2821 participants (1385 women, 1436 men).
lipoprotein analyses
Blood from FHS participants was drawn from each subject at the time of the exam, after a 12-h overnight fast, into tubes containing EDTA (final concentration, 1.5 g/L).
Plasma was separated by centrifugation (1000g, 4°C, 20 min). Plasma lipid and lipoprotein concentrations (total cholesterol, triglycerides, and HDL-C) were measured fresh, using established enzymatic methods, essentially as previously described (25) . These values have been previously reported (26, 27) .
rlp analyses
RLP isolation was based on the removal of apo A-Icontaining particles (HDL) and most apo B-containing particles (LDL, nascent VLDL, and nascent chylomicrons), using an immunoseparation technique [Japan Immunoresearch Laboratories (JIMRO) described previously (16 -18) ], which has been shown to leave remnants of both intestinal and hepatic origin in the unbound fraction. Briefly, monoclonal antibodies (Mabs) to apo A-I and specific Mabs to apo B (JI-H), which do not recognize partially hydrolyzed, apo E-enriched lipoprotein remnants, were immobilized on agarose gel. RLP-C and RLP-TG concentrations were measured in the FHS plasma aliquots that had been frozen at Ϫ80°C until the time of analysis. Plasma was incubated with the gel for 2 h on a JIMRO incubator in Hitachi sample cups (Boehringer Mannheim Diagnostics), after which the gel, containing the bound (non-RLP) lipoproteins, was precipitated by low-speed centrifugation (5 min, 135g). Cholesterol and triglyceride concentrations (RLP-C and RLP-TG, respectively) were then measured in the unbound supernates, using two-reagent enzymatic assays with a sensitive chromophore (Kyowa Medex) for both the RLP-C and RLP-TG measurements on an Abbott Spectrum analyzer (Abbott Diagnostics). The sensitive chromophore is necessary because remnant concentrations are very low in most individuals, particularly in the fasting state, and the final supernate dilution of the assay is 1:61 (by volume Ϫ3 mmol/L (0.125, 0.250, 0.500, 1.000, and 2.000 mg/dL). These were subsequently replaced by calibration factors to obtain more consistent and accurate performance on the Abbott Spectrum. Because the working calibrators were large, serial dilutions of the stock calibrators, they were by definition linear but did not necessarily provide accurate, reproducible calibration. Very small differences in calibrator absorbances corresponded to relatively large differences in concentration in the resulting analyses and thereby led to the the need to manually evaluate the calibrator absorbances to determine acceptance or rejection on the basis of a very narrow acceptable absorbance range for each calibrator. The change to the use of a calibration factor essentially perClinical Chemistry 44, No. 6, 1998 formed the same function. More recently, a set of calibrators that requires no manipulation has been developed at Pacific Biometrics Research Foundation (Seattle, WA) to prevent such problems, but these calibrators were not available at the time the present study samples were analyzed. Cross-over comparisons between the calibration factor and the preset calibrators produced equivalent sample results.
evaluation of frozen plasma
Before analysis of the FHS samples, the relationship between paired fresh and frozen samples was evaluated in a separate set of samples. In the initial fresh/frozen comparison, 40 fasting samples were analyzed for RLP-C and RLP-TG in the fresh state and were then frozen at Ϫ80°C in multiple aliquots for subsequent analysis at multiple time points. A single aliquot of each sample was removed from the freezer for isolation and analysis at 1-, 2-, 3-, and 6-week (no RLP-TG) intervals and at 3-and 6-month intervals. These thawed samples were analyzed under the same preoptimization conditions as the original fresh aliquots, using Kyowa Medex cholesterol reagent, but a non-blanked triglyceride reagent generally used for serum triglyceride measurements; isolations also used Abbott wide-mouthed sample cups. A second comparison, under final, optimized conditions, used 61 fasting samples in which RLP-C and RLP-TG were each measured fresh and at a single frozen time point (frozen 1 week to 3 months). Optimized conditions included incubation in Hitachi sample cups, which provided better mixing characteristics, calibration with the use of calibration factors, and RLP-TG measurements with a sensitive, blanked triglyceride reagent (Kyowa Medex).
statistical analysis
Statistical analyses were conducted with the SAS statistical program (SAS Institute). Student's t-test was used to compare mean values between groups. Categorical values were compared by 2 analysis. Percentiles were determined with the Proc Univariate procedure. The fresh/ frozen sample comparisons were analyzed by paired Student's t-test and correlation analyses. Bias and percentage bias determinations were calculated for each pair and averaged. Because analyses in most clinical laboratories would be performed on fresh samples, the equations for bias derived from the fresh/frozen comparison were applied to results obtained on the FHS samples to provide fresh-equivalent reference ranges.
Results

rlp assay evaluation
Results from the fresh/frozen comparisons on fasting samples indicated small but potentially significant freezer-associated biases. Results of the time-course comparison indicated that the magnitude of the biases in samples with triglyceride concentrations Յ5.65 mmol/L (Յ500 mg/dL) was not directly related to the duration of freez- (28) . Results of the second fresh/frozen comparison, performed under the optimized conditions used for the FHS samples, indicated a small mean bias for RLP-C of 0.013 mmol/L (0.5 mg/dL; 3.5%; r ϭ 0.86; P ϭ 0.097), which did not reach significance, and a small but significant mean bias for RLP-TG of Ϫ0.032 mmol/L (Ϫ2.8 mg/dL; Ϫ7%; r ϭ 0.96; P Ͻ0.001). The derived-fit equations were y ϭ 1.22x Ϫ 0.032 (1.22) for RLP-C and y ϭ 0.95x Ϫ 0.013 (1.14) for RLP-TG (Fig. 1) ; these equations were used to adjust the measurements obtained from the frozen FHS samples to provide fresh- age and gender differences with respect to rlp-c and rlp-tg Relevant biochemical and anthropomorphic characteristics for the FHS participants are presented in Table 1 . Although all of the parameters except for RLP-C and RLP-TG have been previously reported (26, 27) , they are included here for comparison with RLP-C and RLP-TG concentrations. Previously reported parameters that differed significantly between women and men were blood pressure, serum glucose, triglycerides, HDL-C, and LDL-C. However, in the present study we also found significant age-and gender-associated differences in concentrations of both RLP-C and RLP-TG (Table 1) (Tables 2 and 3) , and gender differences for both RLP-C and RLP-TG were evident throughout all age categories. Smoking was positively associated with RLP-C (P Ͻ0.02) and RLP-TG (P Ͻ0.04) concentrations in women, but there was no association in men. Alcohol intake was not associated with RLP concentrations in women or men. We also assessed the influence of menopause on RLP concentrations and found that postmenopausal women (n ϭ 718) had significantly higher RLP-C values than premenopausal women [n ϭ 667; 0.188 Ϯ 0.063 mmol/L (7.3 Ϯ 2.5 mg/dL) vs 0.163 Ϯ 0.049 mmol/L (6.3 Ϯ 1.9 mg/dL), P Ͻ0.0001]. Postmenopausal women also had significantly higher RLP-TG concentrations than premenopausal women (0.225 Ϯ 0.179 mmol/L (19.9 Ϯ 15.8 mg/dL) vs 0.181 Ϯ 0.130 mmol/L (16.0 Ϯ 11.5 mg/dL), P ϭ 0.0001; Table 4 ].
Univariate correlation coefficient analysis indicates that both RLP-C and RLP-TG are significantly positively correlated with total cholesterol, triglyceride, and LDL-C concentrations, and inversely correlated with HDL-C concentrations (Table 5) .
From the RLP-C and RLP-TG data that were generated, we have developed age-and gender-specific distribution ranges (Tables 2 and 3 ), based on 10-year intervals for men and women. From these distribution ranges, we have also calculated cutoff points for low, normal, and increased concentrations. Ranges set for RLP-C were: low, Ͻ0.15 mmol/L (Ͻ6 mg/dL); normal, 0.15-0.25 mmol/L (6 -10 mg/dL); and increased, Ͼ0.25 mmol/L (Ͼ10 mg/ dL). Corresponding RLP-TG cutoff points were also set: smoking, diabetes mellitus, a family history of premature CHD, increased LDL-C, and decreased HDL-C (29). Additional potential lipoprotein risk factors include increased concentrations of lipoprotein(a) (30 -32) , fasting triglycerides (2, 10, 33) , postprandial triglycerides (6, 34, 35) , and lipoprotein remnants (8, 36, 37) , as well as the presence of small dense LDLs (38 -40) . Increases in serum triglycerides are frequently seen in patients diagnosed with CHD and also in segments of the general population that are at highest risk for the development of CHD. However, triglycerides are not significantly and independently associated with CHD in most prospective studies. The difficulty with using plasma or serum triglyceride measurements to assess CHD risk may stem from the variability within the subspecies of TRL particles, as well as the inverse association with HDL-C. It is not possible to distinguish TRLs that are atherogenic from those that are nonatherogenic simply by measuring triglyceride content. It has been hypothesized for many years that lipoprotein remnants are atherogenic (37, (41) (42) (43) . These particles have been difficult to isolate and quantitate, however, because they have so few distinguishing characteristics and come in widely varying sizes that overlap with other similarly composed lipoproteins. Remnants have been separated primarily by density and charge (5, 44) , and studies that have tried to analyze the impact of remnants have often had to rely on indirect methods (43) . Each method that is used to separate the particles called "remnants" will probably isolate slightly different populations. The immunoseparation technique used for the current study is no exception.
The RLP assay relies on two Mabs to bind and sequester all lipoproteins except apo E-and cholesteryl-esterenriched, apo C-poor TRLs, generally considered to be remnants. HDLs are bound by an anti-apo A-I, whereas the apo B-containing lipoproteins are bound by the specific anti-apo B, Mab JI-H (16, 17) . The unbound lipoproteins after incubation with Mab JI-H were carefully characterized by agarose electrophoresis, ultracentrifugation, immunoaffinity chromatography, and electron photomi- All correlation coefficients were significant at P Ͻ0.0001, with the exception of LDL-C with triglycerides in men, which was significant at P Ͻ0.001.
crography. Their characteristics were consistent with the results of previous studies describing remnants in both rats (44) and humans (45) .
In the present study, we have investigated the use of the RLP assay as a possible means of isolating and measuring potentially atherogenic subspecies of TRLs. If the measurement of remnant lipoproteins were indeed a more sensitive indicator of atherogenic TRLs subspecies and if those measurements could provide additional useful information in terms of risk prediction, diagnosis, and monitoring, then the addition of such an assay to the clinical arena would be very beneficial. Preliminary comparisons between patients with coronary disease and individuals without disease in the FHS population indicate that RLP-C and/or RLP-TG are significantly higher in the coronary disease patients (36) . Furthermore, a recent study in postmortem samples by Takeichi et al. showed that individuals that died from sudden cardiac death had significantly higher concentrations of RLP-C and RLP-TG than individuals that died from sudden noncardiac death (46) . In addition, studies in patients at risk for CHD, notably diabetics and those with type III hyperlipoproteinemia, have shown similar results (47, 48) .
The first step in evaluating the assay with regard to CHD, however, is the development of reliable reference ranges based on a large and representative population. Because most population studies, including the FHS, store plasma or serum at Ϫ70 to Ϫ80°C for subsequent biochemical analyses, evaluation of the effects of sample freezing on proposed assays was necessary before developing reference ranges and assessing the clinical utility of the assay in samples stored under these conditions. Previous assay development work by our laboratory has shown that some lipoprotein tests are affected by freezing (11, 49) , whereas others are not (40) . The issue of most concern is the potential for large systematic biases or for time-dependent variability in concentrations that may result from the freezing process and/or its duration (11) . We have documented that, for fasting serum, a single freezing step at Ϫ80°C causes a small increase in RLP-C and a modest concomitant decrease in RLP-TG, compared with fresh serum. Although measurement in fresh samples is preferable, we have determined that the alterations caused by freezing can be adjusted to provide freshequivalent values in previously frozen samples; the FHS RLP-C and RLP-TG concentrations in the present study were subjected to these adjustments to provide reference ranges applicable to clinical settings, where samples are generally analyzed fresh.
Our data indicate that, in fresh samples, an RLP-C value Ն0.25 mmol/L (10 mg/dL) and an RLP-TG value Ն0.40 mmol/L (35 mg/dL) in the fasting state may be considered increased in this population, and that age, gender, and menopausal status have significant effects on RLP-C and RLP-TG concentrations. Abnormal concentrations of RLP-C and RLP-TG are also associated with abnormal concentrations of other lipoprotein parameters.
With a population base of ϳ3000 individuals, we now have sufficient data for comparison of RLP-C and RLP-TG concentrations in individuals diagnosed with CHD to evaluate the efficacy of these determinations. Both case control and prospective comparisons are currently under way.
